Compare TG Therapeutics Inc (TGTX) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Ulta Beauty Inc — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.36B), while Ulta Beauty Inc trades at $542.26 (market cap $23.17B). The key difference: Ulta Beauty Inc is far larger — about 2.8× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Ulta Beauty Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | ULTA | |
|---|---|---|
Market Cap | $8.36B | $23.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $706.82 |
52-Week Low | $26.94 | $450.75 |
Enterprise Value | $8.57B | $25.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
ULTA Beauty trades at $549.23, down 2.64% today, but maintains strong technical support near $539-$530. The company reported solid Q2 2026 earnings with EPS of $6.55 beating expectations of $6.22, while raising full-year guidance. Revenue growth continues at 8.9% year-over-year, though profit margins show slight compression from 12.17% in 2023 to 10.63% in 2025. Analyst consensus remains bullish with a $644 price target representing 17% upside potential.
ULTA presents a compelling growth story with consistent earnings beats and strong institutional support, but faces margin pressure and competitive retail headwinds. The stock's current valuation at 20.54 P/E appears reasonable given its 46.12% ROE and market leadership position. Key risks include consumer spending sensitivity and execution challenges in maintaining growth momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
